

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 8-K

MEDICIS PHARMACEUTICAL CORP

Form 8-K

April 24, 2003

=====

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): April 22, 2003

Medicis Pharmaceutical Corporation  
(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation)	0-18443 (Commission File Number)	52-1574808 (IRS Employer Identification No.)
---	-------------------------------------	--

8125 North Hayden Road Scottsdale, Arizona (Address of Principal Executive Offices)	85258-2463 (Zip Code)
--	--------------------------

Registrant's telephone number, including area code: (602) 808-8800

N/A

-----  
(Former Name or Former Address, if Changed Since Last Report)

=====

Item 7. Financial Statements and Exhibits

(a) Financial Statements of Business Acquired.

Not Applicable.

## Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 8-K

(b) Pro Forma Financial Information.

Not Applicable.

(c) Exhibits.

99.1 Copy of press release, dated April 22, 2003, issued by Medicis Pharmaceutical Corporation

Item 9. Regulation FD Disclosure

On April 22, 2003, Medicis Pharmaceutical Corporation issued a press release summarizing its third quarter 2003 financial results. A copy of the press release appears as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDICIS PHARMACEUTICAL  
CORPORATION  
(Registrant)

Date: April 23, 2003

/s/ Mark A. Prygocki, Sr.  
-----  
-----

Name: Mark A. Prygocki, Sr.  
Title: Executive Vice President,  
Chief Financial Officer,  
Corporate Secretary and  
Treasurer

### EXHIBIT INDEX

EXHIBIT NUMBER -----	DESCRIPTION -----
99.1	Copy of press release, dated April 22, 2003, issued by Medicis Pharmaceutical Corporation.